Video above: Legal challenges following the Dobbs Supreme Court decision

(The Hill) – The Food and Drug Administration (FDA) approved a new generic form of the abortion pill mifepristone this week, drawing upset from conservative voices.

On Tuesday, the FDA sent a letter to Evita Solutions, informing them that their abbreviated new drug application had met the necessary requirements and was approved.

“We have determined your Mifepristone Tablets, 200 mg to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Mifeprex (mifepristone) tablets, 200 mg, of Danco Laboratories,” the FDA’s letter stated.

The FDA first approved mifepristone in 2000. Mifepristone is taken in combination with the drug misoprostol to perform medical abortions, which account for about two-thirds of abortions in the U.S.

Last week, Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary announced the agency would be considering modifying the Risk Evaluation and Mitigation Strategy requirements, citing “recent studies raising concerns about the safety of mifepristone as currently administered.”

This action drew outcry from anti-abortion conservative voices.

Marjorie Dannenfelser, president of the anti-abortion group Susan B. Anthony Pro-Life America, called the decision “unconscionable.”

“These dangerous drugs take the lives of unborn children, place women and underage girls at serious risk, empower abusers, and trample the pro-life laws enacted by states across the nation,” said Dannenfelser, reiterating calls for the Trump administration to reverse the Biden administration’s changes allowing for abortion pills to be sent through the mail.

Sen. Josh Hawley (R-Mo.) echoed these calls, writing on the social media platform X, “This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child.”

The Hill has reached out to Evita Solutions for comment. On the company’s website, it stated its new FDA-approved product would be “coming soon.”

“Medical abortion care is rife with medically unnecessary restrictions and social stigma in the United States. As a result, many people who choose to end a pregnancy may struggle to get the necessary care they need,” the website states.